This company listing is no longer active
9996 Stock Overview
Engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Peijia Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.82 |
| 52 Week High | HK$8.35 |
| 52 Week Low | HK$2.16 |
| Beta | 0.58 |
| 1 Month Change | 14.17% |
| 3 Month Change | n/a |
| 1 Year Change | -59.71% |
| 3 Year Change | -87.24% |
| 5 Year Change | n/a |
| Change since IPO | -90.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9996 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | -0.7% | -4.3% | -3.2% |
| 1Y | -59.7% | -26.9% | 14.4% |
Return vs Industry: 9996 underperformed the Hong Kong Medical Equipment industry which returned -45.8% over the past year.
Return vs Market: 9996 underperformed the Hong Kong Market which returned -2.3% over the past year.
Price Volatility
| 9996 volatility | |
|---|---|
| 9996 Average Weekly Movement | 11.2% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in HK Market | 14.5% |
| 10% least volatile stocks in HK Market | 3.1% |
Stable Share Price: 9996's share price has been volatile over the past 3 months.
Volatility Over Time: 9996's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1,050 | Yi Zhang | www.peijiamedical.com |
Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusMax, an iteration steerable TAVR system; TaurusTrio, a TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymeric leaflet TAVR system; Trilogy, a TAVR System; HighLife, a transseptal mitral value replacement system; Sutra Hemi Valve, a TMV coaptation augmentation system; GeminiOne, a transcatheter edge-to-edge repair system; MonarQ which is transcatheter tricuspid valve replacement systems; TaurusAtlas, a transfemoral balloon catheter; TaurusExplora, a pre-shaped guidewire; and TaurusNavi, an introducer sheath. The company also offers Jasper and Presgo, that are detachable coils; Jasper SS detachable coil; intracranial adjunctive stents; SacSpeed, a balloon dilatation catheter; Tethys AS, an aspiration catheter; Syphonet, a stent retriever; Fastunnel, a balloon microcatheter; Fluxcap, a balloon guiding catheter; NeuroStellar, an intracranial stent; Presgo microcatheter and micro guidewire; Heralder guiding catheter and distal access catheter; Tethys, an intermediate catheter; and Jasper power supply.
Peijia Medical Limited Fundamentals Summary
| 9996 fundamental statistics | |
|---|---|
| Market cap | HK$1.90b |
| Earnings (TTM) | -HK$276.04m |
| Revenue (TTM) | HK$567.41m |
3.3x
P/S Ratio-6.8x
P/E RatioIs 9996 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9996 income statement (TTM) | |
|---|---|
| Revenue | CN¥517.46m |
| Cost of Revenue | CN¥146.18m |
| Gross Profit | CN¥371.28m |
| Other Expenses | CN¥623.02m |
| Earnings | -CN¥251.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 71.75% |
| Net Profit Margin | -48.65% |
| Debt/Equity Ratio | 11.4% |
How did 9996 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/11 02:29 |
| End of Day Share Price | 2024/09/11 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Peijia Medical Limited is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sharon Shi | BOCI Research Ltd. |
| Yuan Gao | China International Capital Corporation Limited |
| Bo Yu | China International Capital Corporation Limited |